Bicara Therapeutics to Report Q2 Results, Provide Business Update in Conference Call

Bicara Therapeutics Director Christy J. Oliger Files Initial Beneficial Ownership Statement

Bicara Therapeutics reshapes board for commercialization push

Bicara Therapeutics Names Jeremy Bender, Christy Oliger to Board

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

Jeet Mukherjee Reiterates Buy on Bicara, Maintains $28 Price Target on Differentiated Ficera Profile and Upside Potential

Bicara CEO Claire Mazumdar Sells 10,000 Common Shares for $283,440

Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of USD 817,447.74 Common Shares

Citizens healthcare analysts hold an analyst/industry conference call

Bicara Therapeutics Grants 191,425 Inducement Stock Options Priced at $28.91 Per Share

Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Holds 2026 Annual Stockholder Meeting

Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors

Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer

Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32

Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)